[Federal Register Volume 67, Number 149 (Friday, August 2, 2002)]
[Notices]
[Pages 50448-50451]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-19594]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Establishment of Prescription Drug User Fee Rates for Fiscal Year 
2003

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the rates 
for prescription drug user fees for fiscal year (FY) 2003. The Federal 
Food, Drug, and Cosmetic Act (the act), as amended most recently by the 
Prescription Drug User Fee Amendments of 2002 (Title 5 of the Public 
Health Security and Bioterrorism Preparedness and Response Act of 2002 
(PHSBPRA or PDUFA III)), authorizes FDA to collect user fees for 
certain applications for approval of drug and biological products, on 
establishments where the products are made, and on such products. This 
notice establishes fee rates by PDUFA for FY 2003 for application fees 
($533,400 for an application requiring clinical data, and $266,700 for 
an application not requiring clinical data or a supplement requiring 
clinical data), establishment fees ($209,900), and product fees 
($32,400). These fees are effective on October 1, 2002, and will remain 
in effect through September 30, 2003. For applications and supplements 
that are submitted on or after October 1, 2002, the new fee schedule 
must be used. Invoices for establishment and product fees for FY 2003 
will be issued in August 2002 using the new fee schedule.

FOR FURTHER INFORMATION CONTACT: Frank Claunts, Office of Management 
and Systems (HFA-20), Food and Drug Administration, 5600 Fishers Lane, 
Rockville, MD 20857, 301-827-4427.

SUPPLEMENTARY INFORMATION:

I. Background

    Sections 735 and 736 of the act (21 U.S.C. 379g and 379h), 
establish three different kinds of user fees. Fees are assessed on: (1) 
Certain types of applications and supplements for approval of drug and 
biological products, (2) certain establishments where such products are 
made, and (3) certain products (21 U.S.C. 379h(a)). When certain 
conditions are met, FDA may waive or reduce fees (21 U.S.C. 379h(d)). 
For FY 2003 through FY 2007 revenue amounts for application fees, 
establishment fees, and product fees are established by PDUFA III. 
Revenue amounts established for years after FY 2003 are subject to 
adjustment for inflation and workload. Fees for applications, 
establishments, and products are to be established each year by FDA so 
that revenues from each category will approximate the levels 
established in the statute, after those amounts have been first 
adjusted for inflation and workload. The revenue levels established by 
PDUFA III continue the arrangement under which one-third of the total 
user fee revenue is projected to come from each of the three types of 
fees: Application fees, establishment fees, and product fees.
    This notice establishes fee rates for FY 2003 for application, 
establishment, and product fees. These fees are effective on October 1, 
2002, and will remain in effect through September 30, 2003.

II. Inflation and Workload Adjustment Process

    PDUFA III provides that fee revenue amounts for each FY after 2003 
shall be adjusted for inflation. The adjustment must reflect the 
greater of : (1) The total percentage change that occurred in the 
Consumer Price Index (CPI) (all items; U.S. city average) during the 
12-month period ending June 30 preceding the FY for which fees are 
being set, or (2) the total percentage pay change for the previous FY 
for Federal employees stationed in the Washington, DC metropolitan 
area. PDUFA III provides for this annual adjustment to be cumulative 
and compounded annually after 2003 (see 21 U.S.C. 379h(c)(1)). No 
inflation adjustment is to be made with respect to fee revenue amounts 
established in the statute for FY 2003.

[[Page 50449]]

    For each FY beginning in FY 2004, PDUFA III provides that fee 
revenue amounts, after they have been adjusted for inflation, shall be 
further adjusted to reflect changes in workload for the process for the 
review of human drug applications (see 21 U.S.C. 379h(c)(2)). No 
workload adjustment is to be made with respect to fee revenue amounts 
established in the statute for FY 2003.
    Since neither inflation nor workload adjustments apply to the 
revenue amounts established in PDUFA III for FY 2003, the levels 
specified in the statute are the amounts that fees set by FDA for FY 
2003 should generate. Those statutory revenue amounts are $74,300,000 
from application fees, $74,300,000 from establishment fees, and 
$74,300,000 from product fees.

III. Fee Calculations

    PDUFA III provides that the fee rates for application, product, and 
establishment fees be established 60 days before the beginning of each 
FY (21 U.S.C. 379h(c)(4)). The fees are to be established so that they 
will generate the fee revenue amounts specified in the statute, as 
adjusted for inflation and workload.

A. Application Fee Revenues and Application Fees

    Application fees are assessed at different rates for qualifying 
applications depending on whether the applications require clinical 
data for safety or effectiveness (other than bioavailability or 
bioequivalence studies) (21 U.S.C. 379h(a)(1)(A)). Applications that 
require clinical data are subject to the full application fee. 
Applications that do not require clinical data and supplements that 
require clinical data are assessed one-half the fee of applications 
that require clinical data. If FDA refuses to file an application or 
supplement, 75 percent of the application fee is refunded to the 
applicant (21 U.S.C. 379h(a)(1)(D)).
    The application fee revenue amount that PDUFA III established for 
FY 2003 is $74,300,000 (21 U.S.C. 379h(b)). For FY 2003 no adjustment 
is to be made for either inflation or workload changes (21 U.S.C. 
379h(c)). Application fees for FY 2003 will be set to generate 
$74,300,000.

B. Estimate of Numbers of Fee-Paying Applications and Establishment of 
Application Fees

    For FY 2003 through FY 2007, FDA will estimate the total number of 
fee-paying full application equivalents (FAEs) it expects to receive 
each year by averaging the number of fee-paying FAEs received in each 
of the five most recent FYs. This use of the rolling average of the 
five most recent FYs is the same method that will also be applied in 
future years in making the workload adjustment.
    In estimating the number of fee-paying FAEs that FDA will receive 
in FY 2003, the 5-year rolling average for the most recent 5 years will 
be based on actual counts of fee-paying FAEs received for FYs 1998 
through 2001. For FY 2002, FDA is estimating the number of fee-paying 
FAEs for the full year based on the actual count for the first 9 months 
and estimating the number for the final 3 months.
    Table 1, under column 2 of this document, shows the total number of 
each type of FAE received in the first 9 months of FY 2002, whether 
fees were paid or not. Column 3 shows the number of FAEs for which fees 
were waived or exempted during this period, and column 4 shows the 
number of fee-paying FAEs received through June 30, 2002. The last 
column estimates the 12-month total fee-paying FAEs for FY 2003 based 
on the applications received through June 30, 2002. All of the counts 
are in FAEs. A full application requiring clinical data counts as one 
FAE. An application not requiring clinical data counts one-half an FAE, 
as does a supplement requiring clinical data. An application that is 
withdrawn or refused for filing counts as one-fourth of an FAE if it 
initially paid a full application fee, or one-eighth of an FAE if it 
initially paid one-half of the full application fee amount.

                          Table 1.--FY 2002 Full Application Equivalents (FAEs) Received Through June 30, 2002, and Projection
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                 Fee Exempt or Waived
                Application or Action                   Total FAEs Received     FAEs Through June 30,    Total Fee Paying FAEs   12-Month Projection for
                                                       Through June 30, 2002             2002            Through June 30, 2002       Fee-Paying FAEs
--------------------------------------------------------------------------------------------------------------------------------------------------------
Applications requiring clinical data                              65.00                    18.00                    47.00                    62.667
--------------------------------------------------------------------------------------------------------------------------------------------------------
Applications not requiring clinical data                           9.00                     3.00                     6.00                     8.00
--------------------------------------------------------------------------------------------------------------------------------------------------------
Supplements requiring clinical data                               43.50                    11.00                    32.50                    43.333
--------------------------------------------------------------------------------------------------------------------------------------------------------
Withdrawn or refused to file                                       0.75                     0.25                     0.50                     0.667
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total                                                            118.25                    32.25                    86.00                   114.67
--------------------------------------------------------------------------------------------------------------------------------------------------------

    In the first 9 months of FY 2002, FDA received 118.25 FAEs, of 
which 86 were fee-paying. Based on data from the last 5 FYs, on 
average, 25 percent of the applications submitted each year come in the 
final 3 months. Thus, dividing 86 by 3 and multiplying by 4 
extrapolates the amount to the full 12 months of the FY and projects 
the number of fee-paying FAEs in FY 2002 at 114.7.
    All pediatric supplements, which had been exempt from fees prior to 
January 4, 2002, were required to pay fees effective January 4, 2002. 
This is the result of section 5 of the Best Pharmaceuticals for 
Children Act that repealed the fee exemption for pediatric supplements 
effective January 4, 2002. Thus, in estimating FY 2003 fee-paying 
receipts we must assume all the pediatric supplements that were 
previously exempt from fees will be subject to fees in FY 2003. In FY 
1998, 8 full fees were exempted for pediatric supplements; the exempted 
number of FAEs for pediatric supplements for FY 1999, FY 2000, FY 2001, 
and FY 2002, respectively, were 5.25, 12.5, 19, and 4.5. Since fees on 
these supplements will be paid for pediatric applications submitted in 
FY 2003, the number of pediatric supplement FAEs exempted from fees 
each year from FY 1998 through FY 2002 (the only years when fees were 
exempted) are added to the total of fee-paying FAEs received each year.
    As table 2 of this document shows, the average number of fee-paying 
FAEs

[[Page 50450]]

received annually in the most recent 5-year period, assuming all 
pediatric supplements had paid fees, and including our estimate for FY 
2002, is 139.3 FAEs. FDA will set fees for FY 2003 based on this 
estimate as the number of full application equivalents that will pay 
fees.

                                                    Table 2.
----------------------------------------------------------------------------------------------------------------
                                                                                                       5-year
      Type of FAE            1998           1999           2000           2001           2002         Average
----------------------------------------------------------------------------------------------------------------
Fee-paying FAEs                118.7          153.0          153.4          107.6          114.7          129.5
----------------------------------------------------------------------------------------------------------------
Exempt pediatric                 8.0            5.3           12.5           19.0            4.5            9.9
 supplement FAEs
----------------------------------------------------------------------------------------------------------------
Total                          126.7          158.3          165.9          126.6          119.2          139.3
----------------------------------------------------------------------------------------------------------------

    The FY 2003 application fee is estimated by dividing the estimated 
number of full applications that will pay fees, 139.3, into the 
statutorily set amount to be derived from application fees in FY 2003, 
$74,300,000. The result, rounded to the nearest one hundred dollars, is 
a fee of $533,400 per full application requiring clinical data, and 
$266,700 per application not requiring clinical data or per supplement 
requiring clinical data.

IV. Adjustment for Excess Collections in Previous Years

    Under the provisions of PDUFA, as amended, if the agency collects 
more fees than were provided for in appropriations in any year after 
1997, FDA is required to reduce its anticipated fee collections in a 
subsequent year by that amount (21 U.S.C. 379h(g)(4)).
    In FY 1998, Congress appropriated a total of $117,122,000 to FDA in 
PDUFA fee revenue. To date, collections for FY 1998 total 
$117,737,470--a total of $615,470 in excess of the appropriation limit. 
This is the only FY since 1997 in which FDA has collected more in PDUFA 
fees than Congress appropriated.
    FDA also has requests for waivers or reductions of FY 1998 fees 
that have been decided but that are pending appeals. For this reason, 
FDA is not reducing its FY 2003 fees to offset excess collections at 
this time. An offset will be considered in a future year, if FDA still 
has collections in excess of appropriations for FY 1998 after the 
pending appeals for FY 1998 waivers and reductions have been resolved.

V. Fee Calculations for Establishment and Product Fees

A. Establishment Fees

    At the beginning of FY 2002, the establishment fee was based on an 
estimate that 354 establishments would be subject to and would pay 
fees. By the end of FY 2002, FDA estimates that 379 establishments will 
have been billed for establishment fees, before all decisions on 
requests for waivers or reductions are made. FDA again estimates that a 
total of 25 establishment fee waivers or reductions will be made for FY 
2002, for a net of 354 fee-paying establishments. FDA will use this 
number, 354, for its FY 2003 estimate of establishments paying fees, 
after taking waivers and reductions into account. The fee per 
establishment is determined by dividing the adjusted total fee revenue 
to be derived from establishments ($74,300,000), by the estimated 354 
establishments, for an establishment fee rate for FY 2003 of $209,900 
(rounded to the nearest one hundred dollars).

B. Product Fees

    At the beginning of FY 2002, the product fee was based on an 
estimate that 2,293 products would be subject to and pay product fees. 
By the end of FY 2002, FDA estimates that 2,348 products will have been 
billed for product fees, before all decisions on requests for waivers 
or reductions are made. Assuming that there will be about 55 waivers 
and reductions made, FDA estimates that 2,293 products will qualify for 
product fees in FY 2002, after allowing for waivers and reductions, and 
will use this number for its FY 2003 estimate. Accordingly, the FY 2003 
product fee rate is determined by dividing the adjusted total fee 
revenue to be derived from product fees ($74,300,000) by the estimated 
2,293 products for a product fee rate of $32,400 (rounded to the 
nearest ten dollars).

VI. Fee Schedule for FY 2003

    The fee rates for FY 2003 are set out in table 3 of this document:

                                Table 3.
------------------------------------------------------------------------
                  Fee Category                    Fee rates for FY 2003
------------------------------------------------------------------------
Applications
  Requiring clinical data                        $533,400
  Not requiring clinical data                    $266,700
  Supplements requiring clinical data            $266,700
Establishments                                   $209,900
Products                                         $32,400
------------------------------------------------------------------------

VII. Implementation of Adjusted Fee Schedule

A. Application Fees

    Any application or supplement subject to fees under PDUFA that is 
submitted after September 30, 2002, must be accompanied by the 
appropriate application fee established in the new fee schedule. 
Payment must be made in U.S. currency by check, bank draft, or U.S. 
postal money order payable to the order of the U.S. Food and Drug 
Administration. Please include the user fee ID number on your check. 
Your check can be mailed to: U.S. Food and Drug Administration, P.O. 
Box 360909, Pittsburgh, PA 15251-6909.
    If checks are to be sent by a courier that requests a street 
address, the courier can deliver the checks to: U.S. Food and Drug 
Administration (360909), Mellon Client Service Center, rm. 670, 500 
Ross St., Pittsburgh, PA 15262-0001. (Note: This Mellon Bank address is 
for courier delivery only.)
    Please make sure that the FDA P.O. Box number (P.O. Box 360909) is 
on the enclosed check. The tax identification number of the U.S. Food 
and Drug Administration is 530 19 6965.

B. Establishment and Product Fees

    By August 31, 2002, FDA will issue invoices for establishment and 
product fees for FY 2003 under the new fee schedule. Payment will be 
due on October 1, 2002. FDA will issue invoices in October 2003 for any 
products and establishments subject to fees for FY 2003 that qualify 
for fees after the August 2002 billing.


[[Page 50451]]


    Dated: July 30, 2002.
Margaret M. Dotzel,
Associate Commissioner for Policy.
[FR Doc. 02-19594 Filed 7-31-02; 9:59 am]
BILLING CODE 4160-01-S